Boehringer Ingelheim has entered into a global research collaboration and license agreement with Circle Pharma to develop a novel precision cancer treatment, leveraging the latter’s proprietary MXMO™ platform. The deal, which is worth up to US$670 M, aligns with Boehringer’s strategic move to further expand its oncology pipeline and offers Circle Pharma the opportunity to conduct research and validate its pipeline across unmet cancer indications. The collaboration comes shortly after Boehringer’s acquisition of cancer drug specialist, Nerio Therapeutics, in a deal worth up to US$1.3 B.